Literature DB >> 27539936

The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.

Stefania Petrosino1,2, Vincenzo Di Marzo1.   

Abstract

Palmitoylethanolamide (PEA) has emerged as a potential nutraceutical, because this compound is naturally produced in many plant and animal food sources, as well as in cells and tissues of mammals, and endowed with important neuroprotective, anti-inflammatory and analgesic actions. Several efforts have been made to identify the molecular mechanism of action of PEA and explain its multiple effects both in the central and the peripheral nervous system. Here, we provide an overview of the pharmacology, efficacy and safety of PEA in neurodegenerative disorders, pain perception and inflammatory diseases. The current knowledge of new formulations of PEA with smaller particle size (i.e. micronized and ultra-micronized) when given alone or in combination with antioxidant flavonoids (i.e. luteolin) and stilbenes (i.e. polydatin) is also reviewed. LINKED ARTICLES: This article is part of a themed section on Principles of Pharmacological Research of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.11/issuetoc.
© 2016 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27539936      PMCID: PMC5429331          DOI: 10.1111/bph.13580

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  179 in total

Review 1.  Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs.

Authors:  V Di Marzo; L De Petrocellis
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 2.  Nerve growth factor: from neurotrophin to neurokine.

Authors:  R Levi-Montalcini; S D Skaper; R Dal Toso; L Petrelli; A Leon
Journal:  Trends Neurosci       Date:  1996-11       Impact factor: 13.837

3.  Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry.

Authors:  Daniela Schreiber; Stephanie Harlfinger; Brit M Nolden; Christoph W Gerth; Ulrich Jaehde; Edgar Schömig; Joachim Klosterkötter; Andrea Giuffrida; Giuseppe Astarita; Daniele Piomelli; F Markus Leweke
Journal:  Anal Biochem       Date:  2006-12-20       Impact factor: 3.365

4.  Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder.

Authors:  W P Farquhar-Smith; A S Rice
Journal:  Anesthesiology       Date:  2001-03       Impact factor: 7.892

5.  Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat.

Authors:  Silvia Conti; Barbara Costa; Mariapia Colleoni; Daniela Parolaro; Gabriella Giagnoni
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

6.  Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma.

Authors:  A Giuffrida; D Piomelli
Journal:  FEBS Lett       Date:  1998-02-06       Impact factor: 4.124

7.  Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis.

Authors:  Antonio Gatti; Marzia Lazzari; Valentina Gianfelice; Annarita Di Paolo; Elisabetta Sabato; Alessandro Fabrizio Sabato
Journal:  Pain Med       Date:  2012-07-30       Impact factor: 3.750

8.  Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells.

Authors:  S Cerrato; P Brazis; M F della Valle; A Miolo; A Puigdemont
Journal:  Vet Immunol Immunopathol       Date:  2009-06-27       Impact factor: 2.046

Review 9.  Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries.

Authors:  Emanuela Esposito; Salvatore Cuzzocrea
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-02-01       Impact factor: 4.388

Review 10.  TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications.

Authors:  Katarzyna Starowicz; Luigia Cristino; Vincenzo Di Marzo
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

View more
  90 in total

1.  Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract.

Authors:  Giorgia Galiazzo; Fiorella Giancola; Agnese Stanzani; Federico Fracassi; Chiara Bernardini; Monica Forni; Marco Pietra; Roberto Chiocchetti
Journal:  Histochem Cell Biol       Date:  2018-06-07       Impact factor: 4.304

2.  Principles of pharmacological research of nutraceuticals.

Authors:  Ruth Andrew; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2017-06       Impact factor: 8.739

3.  The prefrontal cortical endocannabinoid system modulates fear-pain interactions in a subregion-specific manner.

Authors:  Kieran Rea; Fiona McGowan; Louise Corcoran; Michelle Roche; David P Finn
Journal:  Br J Pharmacol       Date:  2018-07-14       Impact factor: 8.739

Review 4.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

5.  Biomarkers of response to alpha-lipoic acid ± palmitoiletanolamide treatment in patients with diabetes and symptoms of peripheral neuropathy.

Authors:  Silvia Pieralice; Riccardo Vari; Alessandra Minutolo; Anna Rita Maurizi; Elvira Fioriti; Nicola Napoli; Paolo Pozzilli; Silvia Manfrini; Ernesto Maddaloni
Journal:  Endocrine       Date:  2019-04-04       Impact factor: 3.633

Review 6.  Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation?

Authors:  Jürg Gertsch
Journal:  Br J Pharmacol       Date:  2017-01-16       Impact factor: 8.739

7.  Palmitoylethanolamide prevents neuroinflammation, reduces astrogliosis and preserves recognition and spatial memory following induction of neonatal anoxia-ischemia.

Authors:  Mariana I Holubiec; Juan I Romero; Juan Suárez; Manuel Portavella; Emilio Fernández-Espejo; Eduardo Blanco; Pablo Galeano; Fernando Rodríguez de Fonseca
Journal:  Psychopharmacology (Berl)       Date:  2018-07-29       Impact factor: 4.530

Review 8.  The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.

Authors:  Stefania Petrosino; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2016-09-29       Impact factor: 8.739

Review 9.  Lipid-metabolizing serine hydrolases in the mammalian central nervous system: endocannabinoids and beyond.

Authors:  Myungsun Shin; Timothy B Ware; Hyeon-Cheol Lee; Ku-Lung Hsu
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-08-16       Impact factor: 4.698

10.  Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial.

Authors:  Giulia Ottaviani; Katia Rupel; Margherita Gobbo; Augusto Poropat; Valentina Zoi; Michela Faraon; Roberto Di Lenarda; Matteo Biasotto
Journal:  Clin Oral Investig       Date:  2018-10-25       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.